CYT News and Press, Cyteir Therapeutics Inc. From 10/12/22

- Poster details the research into CYT-0851 mechanism of action and identification as an inhibitor of monocarboxylate transporter activity Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synt...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a ...

Gainers: Canoo ( GOEV ) +9% . Eargo ( EAR ) +5% . Weatherford International ( WFRD ) +5% . Tremor International ( TRMR ) +5% . Cyteir Therapeutics ( CYT ) +5% . Losers: Stronghold Digital Mining ( SDIG ) -6% . ...

The following slide deck was published by Cyteir Therapeutics, Inc. in conjunction with this event. For further details see: Cyteir Therapeutics (CYT) Investor Presentation - Slideshow

Cyteir Therapeutics press release ( NASDAQ: CYT ): Q2 GAAP EPS of -$0.34. Cash and cash equivalents as of June 30, 2022 were $166.4 million. For further details see: Cyteir Therapeutics GAAP EPS of -$0.34

- Sharpening focus on the pipeline extends cash runway into second half of 2024; Ended quarter with approximately $166 million in cash - IND submission for CYT-1853 postponed to focus on CYT-0851 and preclinical pipeline Cyteir Therapeutics, Inc. (“Cyteir”) (Na...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in th...

Gainers: Heart Core Enterprises (HTCR) +151%. MINISO Group Holding (MNSO) +33%. Imperial Petroleum (IMPP) +33%. Cyren (CYRN) +33%. One Connect Financial Technology (OCFT) +27%. SQL Technologies (SKYX) +27%. Rekor Systems (REKR) +27%. Rubius Therapeutics (RUBY) +24%. Bluejay Diagnostics (BJDX)...

- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Durable responses seen in both solid tumors and hematologic malignancies in the dose escalation with a 44% disease control rate in the r...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentatio...